By Hamza Faisal
Flagship Pioneering, the venture-creation firm behind Moderna, is taking its company-building model outside the United States for the first time — opening a London lab backed by an initial £100 million commitment to create AI-native platform companies.
The firm announced on Monday, November 16, that it has established Flagship Origination Lab, U.K., a dedicated company-creation unit based in London. The lab will conceive, test, fund and build AI-native platform companies focused on human and planetary health and other frontiers of science and technology, operating as part of Flagship Labs, the company's innovation foundry.
A first for Flagship Labs outside the US
The London unit is the first expansion of Flagship Labs' company-creation model beyond Cambridge, Massachusetts, where the firm has spent more than two decades inventing companies from scratch rather than investing in existing startups. Flagship says the new lab builds on three years of partnering and research work across the United Kingdom.
The lab will create a locally rooted company-creation ecosystem in the U.K., connected to Flagship's broader global organisation, including its Pioneering Intelligence and Pioneering Medicines business units. Flagship expects to recruit and train an initial team of around 50 scientist-entrepreneurs and operators in the U.K.
£100 million now, £500 million more in sight
Flagship has committed an initial £100 million to launch and build the new capability. Founder and chief executive Noubar Afeyan said the firm anticipates scaling that commitment through partnerships to attract an additional £500 million, framing the move as a long-term bet on the U.K. as a place to build science-driven companies.
The announcement lands as the U.K. pushes to turn its research strength in life sciences and artificial intelligence into homegrown companies, with London already home to a growing cluster of AI and biotech startups. Flagship's model — pairing scientists with entrepreneurs inside a single foundry to invent companies around new platforms — produced Moderna, the mRNA company that became a household name during the Covid-19 pandemic.
What the lab will actually do
Unlike a traditional venture fund, the Origination Lab will not primarily back outside founders. Instead, its teams will originate ideas internally, test them, fund the most promising ones and build them into standalone companies — the same process Flagship Labs has used in Cambridge to launch dozens of ventures across therapeutics, agriculture and health technology.
Avak Kahvejian, president of Flagship Labs and a general partner at the firm, said the London lab brings the company's company-creation model into a locally rooted U.K. ecosystem. The first companies from the new lab are expected to emerge over the coming years as its initial team of scientist-entrepreneurs gets to work.



